跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TYRUKO natalizumab 300 mg/15 mL concentrate for infusion vial - TGA Drug Approval Details
Approvals
/
TGA
/
TYRUKO natalizumab 300 mg/15 mL concentrate for infusion vial
Approved
STANDARD
TYRUKO natalizumab 300 mg/15 mL concentrate for infusion vial
Sandoz Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
99b820c0a55fd363
Company
Sandoz Pty Ltd
Type
Standard
Approval Details
Approval Id
99b820c0a55fd363
Product Name
TYRUKO natalizumab 300 mg/15 mL concentrate for infusion vial
Artg Id
425612
Artg Name
TYRUKO natalizumab 300 mg/15 mL concentrate for infusion vial
Sponsor
Sandoz Pty Ltd
Company Detail Path
/organization/sandoz-pty-ltd
Artg Date
2025-04-04
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
99b820c0a55fd363
Type
Standard
Back to TGA Approvals
